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Abstract 
Background: The clinical efficacy of the Angiotensin II (AngII) receptor AT2R antagonist EMA401, a novel peripherally-
restricted analgesic, was reported recently in post-herpetic neuralgia. While previous studies have shown that AT2R 
is expressed by nociceptors in human DRG (hDRG), and that EMA401 inhibits capsaicin responses in cultured hDRG 
neurons, the expression and levels of its endogenous ligands AngII and AngIII in clinical neuropathic pain tissues, and 
their signalling pathways, require investigation. We have immunostained AngII, AT2R and the capsaicin receptor TRPV1 
in control post-mortem and avulsion injured hDRG, control and injured human nerves, and in cultured hDRG neurons. 
AngII, AngIII, and Ang-(1-7) levels were quantified by ELISA. The in vitro effects of AngII, AT2R agonist C21, and Nerve 
growth factor (NGF) were measured on neurite lengths; AngII, NGF and EMA401 effects on expression of p38 and 
p42/44 MAPK were measured using quantitative immunofluorescence, and on capsaicin responses using calcium 
imaging.
Results: AngII immunostaining was observed in approximately 75% of small/medium diameter neurons in control 
(n = 5) and avulsion injured (n = 8) hDRG, but not large neurons i.e. similar to TRPV1. AngII was co-localised with 
AT2R and TRPV1 in hDRG and in vitro. AngII staining by image analysis showed no significant difference between 
control (n = 12) and injured (n = 13) human nerves. AngII levels by ELISA were also similar in control human nerves 
(4.09 ± 0.36 pmol/g, n = 31), injured nerves (3.99 ± 0.79 pmol/g, n = 7), and painful neuromas (3.43 ± 0.73 pmol/g, 
n = 12); AngIII and Ang-(1-7) levels were undetectable (<0.03 and 0.05 pmol/g respectively). Neurite lengths were 
significantly increased in the presence of NGF, AngII and C21 in cultured DRG neurons. AngII and, as expected, NGF 
significantly increased signal intensity of p38 and p42/44 MAPK, which was reversed by EMA401. AngII mediated sen-
sitization of capsaicin responses was not observed in the presence of MAP kinase inhibitor PD98059, and the kinase 
inhibitor staurosporine.
Conclusion: The major AT2R ligand in human peripheral nerves is AngII, and its levels are maintained in injured 
nerves. EMA401 may act on paracrine/autocrine mechanisms at peripheral nerve terminals, or intracrine mechanisms, 
to reduce neuropathic pain signalling in AngII/NGF/TRPV1-convergent pathways.
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Background
Neuropathic pain has a prevalence of 1–8% in the gen-
eral population, and is a major unmet medical need due 
to limited efficacy and tolerability of currently available 
drug treatments. Hyperexcitability and abnormal sprout-
ing of primary afferent sensory nerve fibres underpin 
peripheral neuropathic pain [1].
The angiotensin II (AngII) type 2 receptor (AT2R) was 
identified as a novel target for neuropathic pain: several 
small molecule AT2R antagonists with >1000-fold selec-
tivity over the AT1R receptor produced dose-dependent 
analgesia in multiple rodent neuropathic pain models, 
with the analgesia abolished in mice null for the AT2R 
[2]. Our studies in human and rat DRG neurons dem-
onstrated that EMA401, a selective AT2R antagonist, 
inhibited neurite outgrowth and capsaicin responses 
in cultured human and rat DRG neurons, in an in vitro 
model of sensitization [3]. In a recent randomized, dou-
ble-blind, placebo-controlled clinical trial in patients 
with post-herpetic neuralgia, administration of the orally 
active AT2R antagonist, EMA401, for 4 weeks produced 
significant pain relief above placebo and was well-toler-
ated [4].
The underlying mechanisms of AT2R signalling in 
clinical neuropathic pain states, and mode of action of 
the peripherally-restricted AT2R antagonist EMA401, 
require elucidation. We have previously shown that 
AngII, the endogenous ligand for the AT2R, acted 
in  vitro on AT2R resulting in sensitization of TRPV1 
and increased neurite outgrowth in DRG neurons 
via increased cAMP, which were both inhibited in 
the presence of EMA401 [3]. TRPV1, the heat and 
capsaicin receptor, is known to be sensitized when 
phosphorylated by cAMP, and desensitized when 
dephosphorylated [5]. Neurite outgrowth is also sen-
sitive to cAMP levels, and our previous study showed 
the neurite promoting effects of AngII in the pres-
ence of added neurotrophic factors, which have similar 
effects [3]. In animal models of neuropathic pain the 
analgesic action of AT2R antagonists involves inhibi-
tion of enhanced AngII/AT2R induced p38 and p42/
p44 MAPK activation [2].
Systemic AngII is known to be derived from the action 
of kidney derived renin on AngI in the circulation. How-
ever, local renin angiotensin system (RAS) components 
have been described in brain [6], heart, blood vessels 
[7], and DRG [8, 9], constituting potential local sources 
of AngII, separate from the circulating AngII. In addition 
to AngII, other components of the RAS, AngIII and Ang-
(1-7), are also ligands at the AT2R; however the levels 
of these endogenous ligands in clinical peripheral neu-
ropathic tissues and signalling pathways are unknown. 
AngII to AngIII conversion in rodent CNS has been 
reported to mediate descending inhibitory pathways, 
while Ang-(1-7) is a biologically active heptapeptide 
formed endogenously from either AngI or AngII, with 
vasodilatory and antiproliferative activities that oppose 
the constrictive and proliferative effects of AngII [10, 11]. 
Circulating levels of Ang-(1-7) in humans are reported to 
increase following long term administration of ACE and 
AT1 receptor blockers [12–14].
We have studied the expression of AngII, AT2R and 
TRPV1 in clinical tissues, and quantified the levels of 
AngII, AngIII and Ang-(1-7) by ELISA. The effects of 
AngII, the AT2R antagonist EMA401 and the synthetic 
AngII agonist EMA1087 (Compound 21) [15] on calcium 
influx and neurite outgrowth were studied in cultured 
rat DRG neurons. The in vitro effects of AngII, NGF and 
EMA401 on expression of pp38 and pp42/44 MAPK in 
rat sensory neurons were measured using immunofluo-
rescence. AngII, AT2R and TRPV1 expression were also 
studied in cultured human DRG neurons using immu-





All results are given as mean  ±  sem unless otherwise 
stated. Antibodies to AngII (Table  1) were first evalu-
ated by titration on tissue sections of human DRG. Rab-
bit antibodies to AngII showed strong staining of small/
medium diameter (≤50  µm) sensory neurons but not 
large diameter neurons (Figure  1a, b), and showed co-
localisation with TRPV1 (Figure  1c). Mouse antibodies 
showed very similar strongly immunoreactive sensory 
neurons (not shown). Counts of AngII immunoreactive 
small/medium diameter (≤50 µm) neurons showed that 
78.54 ± 2.0% were positive in control hDRG (n = 5) and 
72.13 ± 5.4% in avulsion injured hDRG (n = 8, p = 0.95). 
A comparison of serial sections immunostained with 
AngII (Figure 1b) and AT2R antibody showed that AngII 
and AT2R were co-localised in some small/medium 
diameter (≤50 µm) cells (Figure 1d).
Table 1 Antibodies used for  immunostaining human tis-
sues
Antibody Donor Source Reference Dilution
AngII/III Mouse Serotec Ltd. UK 0500–0300 25–1,000
AngII Rabbit BIOSS-USA bs-0587R 5–1,000
TRPV1 Rabbit GSK C22 10,000
AT2 receptor Goat Santa Cruz sc-48452 50–100
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Serial sections of human peripheral nerve immu-
nostained with antibodies to AngII (Figure  2a), and 
TRPV1 (Figure  2c) showed positive nerve fibres. AngII 
was present in injured human nerve fibres (Figure  2b), 
also shown with the structural nerve marker neuro-
filaments (Figure  2d). Image analysis (% area) of nerves 
immunostained with AngII antibodies showed no 
significant difference between control (n  =  12) and 
injured (n  =  13) human nerves (Figure  2e). AngII lev-
els by ELISA were also similar in control human nerves 
(4.09  ±  0.36  pmol/g, n  =  31), injured nerve trunks 
(3.99  ±  0.79  pmol/g, n  =  7), and painful neuromas 
(3.43 ± 0.73 pmol/g, n = 12) (Figure 2f ). AngIII-specific 
and Ang-(1-7) ELISA levels were undetectable (below 
<0.03 and <0.05 pmol/g respectively), indicating that the 
major angiotensin analogue in these human nerve tissue 
extracts is AngII.
Results of in vitro studies
These studies showed co-expression of AT2R, AngII 
and TRPV1 in small diameter cultured hDRG neu-
rons using immunofluorescence (Figure  3). AngII 
was expressed in 75.6 ±  6.3% small diameter neurons 
(≤50  μm diameter, 509 neurons), with a mean diam-
eter of 37.5 ± 1.8 μm, and co-localised with virtually all 
AT2R positive hDRG neurons. AngII was co-localised 
in cultured DRG neurons with AT2R and TRPV1, as 
illustrated in Figure 3h–k. AngII treated rDRG neurons 
showed a significant increase in pp42/44 signal inten-
sity compared to vehicle treated controls (*P  <  0.05), 
similar to the positive controls treated with NGF 
(*P < 0.05, Figure 4). Signal intensity was reduced to an 
extent in cultures treated with AngII combined with 
EMA401 (P  >  0.05). Similar increases in pp38 signal 
intensity were observed in NGF (*P < 0.05) and AngII 
treated neurons (*P  <  0.05), which were reduced to 
an extent after co-incubation with EMA401 (P  >  0.5, 
Figure 4).
The average neurite lengths from each group were nor-
malised to vehicle treated controls (BSF2 medium); neur-
ite lengths were significantly increased in rDRG neurons 
treated with combined AngII and NTFs (170.6 ±  7.3%, 
***P  <  0.001, n  =  3), or AngII alone (120.5  ±  12%, 
*P < 0.05, n = 4), or EMA1087 (C21) alone (159.2 ± 11%, 
**P < 0.01, n = 4), compared with vehicle treated controls 
(694.7 ± 55 μm, n = 5), (Figure 5a, b).
Calcium imaging showed that in hDRG, the second 
response to capsaicin (control) in the absence of added 
drugs was reduced due to repeat stimulation (tachy-
phyllaxis) (83.1  ±  2.3%, n  =  23). Capsaicin responses 
were significantly enhanced in the presence of 100  nM 
AngII, compared with responses in the absence of AngII 
Figure 1 IHC in human DRG tissues. Serial sections of post-fixed human avulsion injured DRG immunostained with rabbit antibodies to AngII (a) 
and TRPV1 (c). Arrows indicate co-localising cells. Similar serial sections of post-fixed human avulsion injured DRG immunostained with antibodies to 
AngII (b) and AT2R (d). Arrows indicate co-localising cells. Scale bar 50 microns.
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(n = 4, ***P < 0.01); this enhancement was not observed 
in the presence of the MAPK inhibitor PD98059 (1 μM, 
n =  8) (Figure  5c). Similarly, the second response (con-
trol) in rDRG neurons was reduced to 89.5  ±  7.7% 
(n  =  14), but showed significant enhancement of cap-
saicin responses in the presence of AngII (198.5 ± 29%, 
n = 16, ***P < 0.001), and EMA1087 (C21, 123.2 ± 10%, 
n  =  4, *P  =  0.013). While rDRG neurons also showed 
sensitization after AngII treatment, the magnitude was 
less than that observed in hDRG neurons. AngII medi-
ated sensitization was not observed in combination with 
PD98059 (n  =  9 neurons), the protein kinase inhibitor 
staurosporine (n = 11 neurons), and the TrkA inhibitor 
GW441756 (n = 12 neurons), (Figure 5d).
A schematic diagram showing the signalling pathway 
involving AT2R and TRPV1 is shown in Figure 6.
Discussion
In this study we observed that AngII was expressed in 
a large proportion of small diameter neurons in human 
DRG, co-localised with AT2R and TRPV1, and that 
AngII levels were preserved in injured human DRG and 
nerve tissues. Co-localisation of AngII expression with 
AT2R in hDRG, and its levels in injured nerves, supports 
Figure 2 IHC in human nerve tissue. Serial sections of post-fixed human peripheral nerve immunostained with antibodies to AngII (a, b) showing 
co-localisation with TRPV1 (c) and the structural nerve marker Neurofilament (NF) (d). Scale bar 100 microns. Graph showing image analysis (% 
area) of AngII immunoreactivity in control (n = 12) and injured (n = 13) nerves expressed as a ratio to the structural nerve marker neurofilaments 
(e). Graph showing AngII levels by ELISA were similar in control human nerves (n = 31), injured human nerve trunks (n = 7), and painful human 
neuromas (n = 12) (f).
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the concept of an intrinsic neuronal angiotensinergic 
system, and suggests that EMA401 may act via auto-
crine/intracrine in addition to paracrine mechanisms in 
DRG neurons, to reduce augmented neuropathic pain 
signalling.
Quantitative ELISA studies in human tissues showed 
that the major AT2R ligand in human peripheral nerves 
was AngII, and that its levels were similar in injured 
human nerves and painful neuromas compared to con-
trol nerves. Evidence supports the concept of an intrin-
sic neuronal angiotensinergic system, with intraneuronal 
AngII formation in sensory neurons, which appears to 
be maintained in injured neurons—hence its potential 
autocrine/intracrine role in pathological nociceptive 
mechanisms. AngIII and Ang-(1-7) levels were below 
the detection limits, in accord with other studies [8]. 
Previous studies have also described dense AngII posi-
tive nerve fibres and high levels in peripheral organs 
[16], and localisation in small and medium sized neu-
rons in trigeminal ganglia [8, 9]. In situ hybridization in 
rat trigeminal ganglia have revealed expression of AngII 
precursor Angiotensinogen (Ang-N) mRNA in the cyto-
plasm of numerous neurons, and post in situ hybridiza-
tion immunocytochemistry marked some of these for 
Ang II; substance P was found colocalized with Ang II 
[8]. These studies support intraneuronal AngII forma-
tion in sensory neurons, separate from circulating AngII, 
and its potential autocrine/intracrine role in nociceptive 
mechanisms.
It is important to note that we have measured AngII 
levels in human nerves and DRG by ELISA in frozen tis-
sue extracts; as AngII may degrade when extracted in fro-
zen tissues, freshly extracted tissues need to be studied in 
future for AngII, other putative endogenous RAS ligands, 
and their metabolites. The levels obtained in our study 
are higher than those reported in other studies of rat and 
human trigeminal ganglia [8, 9], and may reflect differ-
ences in peptide extraction prior to assay.
Injury and associated inflammation may increase 
local AngII, contributing to sensitization of nociceptors, 
Figure 3 Immunofluorescence in cultured hDRG neurons. IF images of cultured hDRG neurons positive for the neuronal marker PGP9.5 (a, red), co-
localised with AngII expression in small diameter neuron (yellow in merged image, b), but not in large neuron, and AngII expression alone (c, green). 
Bar 50 μM. IF images showing co-localization of Gap43 (green, d), AT2R (red, e), and AngII (blue, f) in small diameter cultured hDRG neurons; merged 
AT2R and AngII (g). Bar  20 μm. Co-localization of AT2R (red, h), TRPV1 (blue, i), AngII (green, j) and the merged image (k). Bar 10 μm.
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particularly in sprouting nerve fibres. The molecu-
lar regulation of AT2R and AngII expression in injured 
human or rodent sensory neurons is unknown, and may 
be influenced by target-organ derived or intrinsic fac-
tors. In our previous study [3], AT2R levels were reduced 
in human nerve segments proximal to injury (lesion dis-
tal to the DRG, or ‘peripheral axotomy’), but they were 
preserved or high in chronic painful neuromas, which 
comprise regenerating nerve fibres. These AT2R recep-
tor level changes parallel those of key pain receptors and 
ion channels regulated by target-derived growth fac-
tors e.g. TRPV1, Nav 1.7 and Nav1.8 by NGF after nerve 
injury. The mode of analgesic action of EMA401 may 
involve inhibition of augmented AngII/AT2R signalling 
in NGF convergent pathways, a postulate which is sup-
ported by our in vitro results, described below. The lack 
of CNS penetration of EMA401, and the time-course of 
its clinical effects in patients with post-herpetic neuralgia 
(i.e. gradually progressive over 4  weeks, unlike anticon-
vulsants) argue against AngII acting as a classical neuro-
transmitter in dorsal spinal cord.
Co-expression of AngII, AT2R and TRPV1 was 
observed in cultured small diameter hDRG neurons 
using immunofluorescence, in accord with the hDRG 
tissue findings. AngII was co-localised in cultured 
DRG neurons with AT2R and TRPV1, as illustrated in 
Figure 4 pp42/44 and pp38 expression in cultured rDRG neurons. IF images of pp42/44 expression (upper panel), and pp38 expression (lower 
panel) in vehicle treated rDRG neurons (control 0), or treated with NGF, AngII, or AngII + EMA401 (a). Graph showing quantitation of signal intensity 
for pp42/44 (b), and pp38 expression (c).
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Figure  3h–k. In AngII treated rat neuronal cultures we 
observed significantly increased levels of pp38 and pp42, 
similar to the effect of NGF, which were reduced in the 
presence of EMA401. These results indicate that AngII 
mediated sensitization involves p38 and p44/42 phospho-
rylation, and that EMA401 is effective in blocking this 
in vitro, in agreement with animal models of pain [2, 17]. 
It appears that the mechanism of AngII mediated p38 
and p44/42 phosphorylation involves interaction of the 
AT2R and TrkA, which underlies neuronal differentiation 
of NG108 cells [18], sensitization of mature neurons as 
observed in this study, and increased neurite outgrowth.
In our previous study [3], neurons treated with 
combined AngII and NTFs (NGF, GDNF, NT3) had 
significantly longer neurites compared with NTF treat-
ment alone, suggesting a synergistic effect of AngII with 
the neurotrophic factors, which was reduced by co-treat-
ment with EMA401. In this study neurite lengths were 
also significantly increased in neurons treated with AngII 
and EMA1087 (C21) alone, but less than with added 
NTFs. The effect of EMA401 on neurites was dimin-
ished outgrowth, rather than degeneration of established 
neurites. Thus AngII treatment of DRG neurons leads 
to increased neurite length and TRPV1 sensitization by 
increased cAMP, both of which are blocked by EMA401 
[3]. While AT2R activation appears to have a synergistic 
effect with TrkA, other pathways such as PI3K [19] may 
also be involved, and need investigation. Other studies 
Figure 5 Effect on neurite length and calcium imaging. Image of an AngII treated DRG neuron showing β tubulin immunofluorescent cell soma 
and neurites (a), bar 200 μm. Graph showing comparative neurite lengths of neurons treated with BSF2 (medium alone), and significant increase 
with AngII + NTFs, Ang II or EMA1087 (b). AngII mediated sensitization of hDRG neurons was reversed in the presence of the MAPK inhibitor 
PD98059 (c). The commercial AT2R agonist EMA1087 (Compound 21) also caused significant sensitization of capsaicin responses. AngII mediated 
sensitization was abolished in the presence of PD98059, staurosporine, and TrkA inhibitor GW441756 (d).
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have reported a role for the AT2R in mediating neurite 
outgrowth in  vitro via estrogen activation [20, 21], and 
in a rodent model of inflammatory hypersensitivity 
[22]. These mechanisms may contribute to the analgesic 
effects of AT2R antagonists in such animal models, and in 
patients with chronic pain, particularly those more prev-
alent in females.
Our finding that AngII and EMA1087 (C21), a small 
molecule AT2R agonist, caused neurite outgrowth in our 
assay is in agreement with the neurite promoting effects 
of C21 previously described in the neuroblastoma-gli-
oma hybrid NG108 cells, that was blocked by the AT2R 
receptor antagonist (PD-123,319) [15, 23]. PD123,319 
was effective in reducing neurite growth in a CFA inflam-
matory pain rodent model [22], and EMA401 inhibited 
neurite outgrowth in  vitro [3], confirming their antago-
nist effects at the AT2 receptor, and potential efficacy 
in pain states associated with abnormal nerve sprout-
ing. Conceptually, while promoting AT2 receptor medi-
ated neuronal outgrowth could be beneficial after 
certain pathologies (e.g. stroke), aberrant or collateral 
neuronal regeneration with hypersensitivity may under-
pin some painful conditions in the periphery mediated 
via AT2R [22], in accord with our clinical efficacy data 
with EMA401 in postherpetic neuralgia patients, and 
human DRG nociceptor models in vitro [3, 4]. An impor-
tant consideration is that the neurite promoting effects 
of C21 described previously in NG108 cells are derived 
from undifferentiated neuroblastoma-glioma hybrid 
cells, presented as % cells with neurites [18], with neur-
ite extension representing neuronal differentiation of the 
NG108 cells, and AngII effects measured by the number 
of cells expressing neurites. This reflects neuronal differ-
entiation, with C21 promoting the neuronal phenotype. 
The findings of our study are, however, derived from 
measurements of neurite lengths from mature, well dif-
ferentiated neurons, and describe the effects of AngII 
on neurite lengths in individual neurons, relevant to 
hyperinnervation.
As AT2R is a GPCR, the AngII mediated increase 
in cAMP [3] is in keeping with adenylyl cyclase activa-
tion, likely to involve a Gαs mechanism. The consequent 
TRPV1 sensitization was not observed in the presence of 
the MAP kinase inhibitor, PD98059 in hDRG and rDRG 
neurons in this study. AngII effects have been associ-
ated with increased neuronal excitability and promo-
tion of neurite outgrowth via multiple mechanisms of 
AT2R activation, depending on the cell type [19]. cAMP 
is also known to activate MAPK to stimulate cell growth 
[24], which in post-mitotic non-dividing neurons may 
manifest as neurite outgrowth. The increased pp38 and 
pp44/42 expression in AngII treated neurons indicate 
that AngII mediated neurite outgrowth and neuronal 
sensitization both involve MAPK/ERK activation, that 
is attenuated by EMA401. AngII thus appears to have 
similar effects as NGF in causing neurite outgrowth and 
TRPV1 sensitization [25], but not in the presence of stau-
rosporine, PD98059 (MAPK inhibitor) and GW441756 
(TrkA inhibitor).
Our results showed that both AngII and its analogue 
EMA1087 (C21) caused TRPV1 sensitization, suggest-
ing that like AngII, C21 has a pro-nociceptive effect. 
While the effects of EMA1087 are more similar to AngII 
for neurite outgrowth but less so in sensitization effects, 
EMA1087 did show significantly enhanced responses as 
did AngII. EMA1087 is a synthetic molecule and AngII 
a peptide, which could explain differential effects in 
assays. AngII appeared to result in greater sensitization 
of human neurons compared with rat neurons, possibly 
reflecting a species specific difference.
Previous studies have shown pro-inflammatory effects 
of AngII in a variety of tissues including kidney, heart and 
blood vessel wall, by up-regulating the expression of both 
AT1R and AT2R, and activation of a number of signalling 
pathways including p44/42 MAPK, p38 MAPK, c-JUN 
and NF-κB [26, 27]. AngII and the inflammatory media-
tor lipopolysaccharide (LPS) are reported to upregulate 
the expression of AT1R, AT2R and LOX-1, and IL-1β in 
cardiomyocytes, with activation of MAPKs, c-Jun and 
NF-kB, suggesting a positive feedback between AngII and 
inflammation [28]. CD68 positive tissue macrophages 
are also reported to increase expression of angiotensino-
gen and renin in a model of inflammatory hypersensi-
tivity [22]. There is thus potential for EMA401 to block 
a number of convergent pathways activated by a variety 
of inflammatory mediators. The sensitizing effect of NGF 
is well known [25, 29–31] and is the basis of our in vitro 
Figure 6 Diagram indicating the pathway involved in AngII and 
TRPV1 signalling, with activation of p38 (MAPK) and p44/42 (ERK) and 
their inhibition by EMA401 in DRG neurons.
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hDRG model of hypersensitivity, modelling the elevated 
NGF levels observed in tissues from chronic pain condi-
tions [32–34]; AngII treatment caused further sensitiza-
tion, suggesting functional synergy between AT2R and 
TrkA. Other pathways need investigation, such as GDNF 
signalling, which may have similar additive effects.
AngII has been reported to increase K+ channel activity 
in hippocampal neurons, that was reversed by the AT2R 
antagonist PD123,319 [35]. In a recent study, this mecha-
nism of hyperpolarisation was proposed to underlie the 
lack of pain in Buruli ulcers caused by mycolactone, the 
polyketide product of m. ulcerans [36]. While this may 
reflect differences in signalling between hippocampal 
and DRG neurons, a number of clinical and neuropatho-
logical aspects of Buruli ulcer have drawn caution against 
such an interpretation [37].
Conclusion
AngII and AT2R are co-expressed in nociceptive human 
sensory neurons, and the levels of AngII, the major 
endogenous ligand in human peripheral nerves, are pre-
served after injury. AngII induces p38, p42/p44 mito-
gen activated protein kinase (MAPK) activation, neurite 
outgrowth in adult rat DRG neurons, and sensitization 
of adult rat and human DRG neurons that is blocked by 
EMA401. Hence increased AngII/AT2R signalling in 
DRG neurons secondary to peripheral nerve injury may 
have a key role in chronic pain mechanisms, including 
neuropathic pain. The mode of EMA401 analgesic action 
appears to involve inhibition of augmented AngII/AT2R 
induced p38 and p42/p44 MAPK activation, and hence 
inhibition of DRG neuron hyperexcitability and sprout-
ing of DRG neurons. EMA401 is likely to be most effec-
tive in conditions of hypersensitivity associated with 
abnormal nerve sprouting, where AngII may synergize or 
augment NGF mechanisms. Selective AT2R antagonists 
represent a new class of analgesics for improved relief of 
neuropathic pain.
Methods
Immunostaining for Angiotensin II (AngII) in human tissues
Tissues
A range of tissues was used in this study obtained with 
consents and approvals as described previously [3], 
including Local Research Ethics Committee, Royal 
National Orthopaedic Hospital, Stanmore, UK, Material 
Transfer Agreement, and Netherlands Brain Bank. Speci-
mens were snap frozen in liquid nitrogen and stored at 
−70°C until use or immersed in Zamboni’s fixative (2% 
w/v formalin, 0.1  M phosphate, and 15% v/v saturated 
picric acid) for 2  h and stored in phosphate buffered 
saline (PBS) containing 15% sucrose, 0.01% azide.
Immunohistology
Tissues were supported in optimum cutting tissue (OCT) 
medium (RA Lamb Ltd, Eastbourne, UK). Tissue sections 
(15 µm thick) were collected onto coated glass slides and 
post-fixed in 4% w/v paraformaldehyde in 0.15 M phos-
phate buffered saline (PBS) for 30 min (for frozen section 
only). Endogenous peroxidase was blocked by incubation 
in methanol containing 0.3% w/v hydrogen peroxide for 
30 min. After rehydration with PBS buffer, sections were 
incubated overnight with primary antibody using a range 
of dilutions (Table 1).
Sites of primary antibody attachment were revealed 
using nickel-enhanced, avidin–biotin peroxidase (ABC-
Vector Laboratories, Peterborough, UK) as previ-
ously described [38]. Sections were counter-stained for 
nuclei in 0.1% w/v aqueous neutral red, dehydrated and 
mounted in xylene-based mountant (DPX; BDH/Merck, 
Poole, UK), prior to photomicrography.
Analysis of data
DRG
Antibody-immunoreactive, nucleated neurons in sensory 
ganglia (DRG) were counted and their diameter assessed 
using a calibrated microscope eyepiece graticule and 
expressed as % total; image analysis (% area) of nerve sec-
tions has been described previously [3].
ELISA for AngII, AngIII and Ang‑(1‑7)
AngII ELISA
Frozen tissue samples of control normal nerve (n = 31), 
injured nerves (n =  7), and painful neuromas (n =  12), 
were weighed and extracted in boiling 0.5 M acetic acid 
for 10  min. Extracts were then concentrated and de-
salted by applying 0.2  ml extract to an activated Sep-
Pak column, washed and desalted with water containing 
0.1% TFA. Bound peptides were eluted from the columns 
using 1 ml of 80% acetonitrile containing 0.1% TFA. The 
eluate was evaporated to dryness using a speed-vac over-
night. Each vial was reconstituted in 1× assay buffer sup-
plied by the manufacturer (see below).
A human specific AngII/AngIII immunoassay kit (EK-
002-12, reacting 100% to AngII and AngIII, Phoenix 
Pharmaceuticals, Burlingame, California, USA) was used 
according to the manufacturer’s instructions (but note 
AngIII specific immunoassay kit described below showed 
undetectable levels of AngIII in these nerve extracts). 
AngII standard (0.04–25  ng/ml) and specimens (50  µl) 
were added in duplicate and the mean used for subse-
quent analysis. The absorbance at 450  nm in each well 
was measured using a plate reader. Standard curve was 
plotted using a log scale and the concentration of human 
AngII in each specimen determined using Excel software.
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In order to determine the recovery of AngII after 
extracting in boiling in acetic acid and concentrating 
using a Sep PaK, 200 µl of standard (at 1 nmol/ml) was 
added to 800 µl of boiling acetic acid for a further 10 min, 
and after cooling 200 µl was applied to Sep Pak and dried 
overnight as above. This was reconstituted with 200 µl of 
assay buffer and 50 µl used for assay in duplicate.
AngIII
A human specific AngIII immunoassay kit (USCN Life 
Sciences ELISA kit, E92312Hu, Diagenics Limited, Mil-
ton Keynes, England) that reacts 100% to AngIII and 
with no significant cross-reactivity with analogues, was 
used according to the manufacturer’s instructions. AngIII 
standard (6.17–500  pg/ml) and specimens (50  µl) were 
added in quadruplicate and the mean used for subse-
quent analysis. The absorbance at 450  nm in each well 
was measured using a plate reader. Standard curve was 
plotted and the concentration of human AngIII in each 
specimen determined using Excel.
Ang‑1‑7
A human specific Ang-1-7 immunoassay kit (USCN Life 
Sciences ELISA kit, E86085Hu, Diagenics Limited, Mil-
ton Keynes, England), reacting 100% to Ang-(1-7) and 
no significant cross-reactivity with analogues, was used 
according to the manufacturer’s instructions. Ang-(1-
7) standard (12.35–1,000  pg/ml) and specimens (50  µl) 
were added in quadruplicate and the mean used for sub-
sequent analysis. The absorbance at 450 nm in each well 
was measured using a plate reader. Standard curve was 
plotted and the concentration of human Ang-(1-7) in 
each specimen determined using Excel.
In vitro studies
Preparation of hDRG neurons
hDRG were obtained from five patients with brachial 
plexus avulsion undergoing nerve repair surgery, excised 
as a necessary part of surgical repair i.e. redundant tissue; 
ganglia were enzyme digested, mechanically dissociated 
and plated on collagen and laminin coated MatTek dishes 
(MatTek Corp USA), in Ham’s F12 medium containing 
10% HIFCS (heat inactivated fetal calf serum), penicillin/
streptomycin (100 μg/ml each), NTFs (NGF 100 ng/ml, 
GDNF and NT3 50 ng/ml each), as previously described 
[3], for 48 h at 37°C before further studies.
Immunofluorescence for AngII, AT2R, TRPV1 in hDRG neurons
Cultures were fixed in 4% PFA for 30 min, permeabilised 
with chilled methanol (−20°C, 3 min), rehydrated in PBS 
and incubated in primary antibodies to goat anti AT2R 
(SC48452, 1:200, Santa cruz), rabbit anti TRPV1 (1:500, 
GSK), or goat anti β tubulin (1:200 Abcam), mouse anti 
AngII (Serotec 1:200), rabbit anti PGP9.5 (1:500, Ultra-
clone, RA95/06), mouse anti Gap43 (1:200, Sigma, UK), 
and visualised with secondary antibodies (1:200 each, 
Life Technologies, U.K.), donkey anti mouse (Alexa 
488), donkey anti rabbit (Alexa 350), and donkey anti 
goat (Alexa 546), incubated for 1  h at room tempera-
ture, and mounted on glass slides in Citifluor mounting 
medium with the antifade agent DABCO (Sigma, UK). 
TIFF images were acquired using widefield fluorescence 
optics with an upright Olympus microscope BX43, and 
cooled CCD camera (Coolsnap), using uv illumination, 
and Cellsens software (Olympus, Japan). Cell counts 
were obtained for neurons expressing AT2R, AngII and 
TRPV1, and neuronal diameters were measured using 
Cellsens software.
Calcium imaging in human DRG neurons
48  h after plating, hDRG neurons were loaded with 
2  μM Fura2 AM, and responses to capsaicin, AngII, 
and EMA1087 (C21), were imaged as before [3]. In each 
experiment, capsaicin sensitive neurons were identified 
with a brief 200 nM capsaicin stimulus (30 s), and wash-
out of medium. After a rest period of 40 min, a second 
capsaicin stimulus, of 1 μM was applied with or without 
drugs. The effects of the kinase inhibitor staurosporine, 
MAPK inhibitor PD98059 and TrkA inhibitor GW441657 
on AngII mediated sensitization were determined by 
adding either one of the inhibitors 10 min prior to add-
ing AngII, followed 10 min later, by the second capsaicin 
stimulus. The second capsaicin response was normalised 
to the first, for calculating the percent response, and the 
average calculated for each group.
Preparation of rDRG neurons
Bilateral DRG from all levels of 6 adult female Wistar rats 
were isolated and plated as before [3], in collagen/laminin 
coated glass bottom plastic petri dishes (MatTek, USA), 
at 1,000 neurons/dish, in BSF2 medium without NTFs for 
pp38 and pp42 immunofluorescence and neurite length 
assay, and with NTFs for calcium imaging, at 37°C. Cal-
cium imaging studies in rat DRG neurons were carried 
out as for human neurons above.
Immunofluorescence for pp38 and pp42 expression in AngII 
and EMA401 treated adult rat DRG neurons
48  h after plating, duplicate dishes were treated with 
AngII (10  nM), AngII  +  EMA401 (10 and 100  nM 
respectively), 100  nM EMA401, NGF (100  ng/ml) or 
vehicle treated (control 0), for 30 min at 37°C, then fixed 
with 4% PFA for 30 min for immunostaining.
Following fixation, and 3  min permeabilisation with 
methanol at −20°C, the neurons were incubated in rab-
bit polyclonal antibody to phospho-p38MAPK pThr180 
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(1:200, PA1-14304, Thermo Scientific, USA), or rabbit 
monoclonal antibody to phospho –p44/42 (ERK 1/2, 
1:200, 4370S New England Biolabs, UK), for 1 h at room 
temperature, visualised with secondary antibody Alexa 
fluor 546 goat anti rabbit (1:200, Life Technologies, USA), 
incubated for 45 min, and mounted in glycerol contain-
ing antifade agent DABCO (Sigma UK) on glass slides. 
TIFF fluorescence images were acquired with an upright 
Olympus BX43 widefield fluorescence microscope with 
the same acquisition settings for all groups, using Cells-
ens software (Olympus, Japan). Signal intensity was 
measured after background substraction, from at least 
120 neurons in each group, from at least three experi-
ments using Image J software (N.I.H. USA), and normal-
ised to controls.
Effect on neurite length
rDRG neurons were prepared as above in BSF2 medium, 
and 48  h later duplicate dishes were treated with AngII 
(10 nM), NTFs (NGF 100 ng/ml, GDNF and NT3 50 ng/
ml each), 10  nM EMA1087 (Compound 21) or vehicle 
treated, for 48 h at 37°C. Cultures were fixed and immu-
nostained with mouse Gap43 (1:200, Sigma, UK), visual-
ised with FITC conjugated Alexa Fluor goat anti mouse 
(1:200, Life Technologies), for 45 min each, and mounted 
on glass slides. TIFF images were acquired with an Olym-
pus upright microscope as above. The longest neurite 
lengths were measured for calculating the average from 
approximately 50 neurons in each group and normalised 
to vehicle treated controls.
Student’s t test was used to compare groups, and 
P < 0.05 was considered statistically significant.
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